Also, Goldman Sachs recently added to the bearish outlook on Moderna, downgrading the stock to Hold and cutting its price target from $99 to $51, citing continued revenue guidance reductions and ...

This is a significant shift from the previous quarter when Moderna’s Q3 2024 results showcased resilience. Goldman Sachs Weighs in on Moderna Stock While Moderna’s Q4 earnings may represent a ...

Goldman Sachs trims its staff, cutting what it deems to be the underperformers. This year, VPs stand to be big targets, BI ...

Mutual of America Capital Management LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.6% during the ...

MRNA has been the topic of several other reports. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $99 ...

Hedge funds unwound positions in single stocks on Friday at the largest amount in over two years, with some activity ...